- $1.12bn
- $831.90m
- $261.29m
- 81
- 28
- 75
- 64
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 6-K |
Standards: | USG | USG | USG | USG | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 252 | 250 | 286 | 293 | 261 |
Cost of Revenue | |||||
Gross Profit | 207 | 205 | 234 | 240 | 210 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 235 | 244 | 268 | 297 | 293 |
Operating Profit | 16.9 | 6.17 | 18.2 | -3.34 | -31.7 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 25.7 | 14 | 22.6 | 4.71 | -17.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | 22.6 | 9.64 | 7.81 | -0.166 | -21.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 22.6 | 9.64 | 7.81 | -0.166 | -21.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 22.6 | 9.64 | 7.81 | -0.166 | -21.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.47 | 0.208 | 0.181 | -0.004 | -0.458 |